首页 › 基金 › Davern Capital Partners, LP › VRDN
Davern Capital Partners, LP 对 VRDN 的持仓历史
VIRIDIAN THERAPEUTICS INC · 医疗保健
Davern Capital Partners, LP 在 Q3 2026 的 13F 申报中披露持有 VRDN(VIRIDIAN THERAPEUTICS INC)560,710 股,市值约 US$11.5M,约占其申报组合的 2.25%,在其申报持仓中市值排名第 16 位。 Davern Capital Partners, LP 最近 4 个申报季度中有 3 个季度披露了 VRDN 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-11-12 · 来源: SEC EDGAR Form 13F-HR
Davern Capital Partners, LP 对 VRDN 的持仓演变
Davern Capital Partners, LP 于 Q4 2025 首次披露 VRDN 持仓:261,615 股(约 US$8.1M)。 该持仓在 Q3 2026 达到峰值 560,710 股,市值约 US$11.5M。 在 3 次申报中,Davern Capital Partners, LP 1 次增持、0 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 560,710 股、市值约 US$11.5M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 261.62K | $8.14M | 新进 |
| Q1 2026 | 302.46K | $5.92M | 增持 |
| Q3 2026 | 560.71K | $11.55M | 新进 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 VRDN 与 13F 数据
VRDN(VIRIDIAN THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 37 只申报持有 VRDN,申报仓位最大的包括:Bellevue Group AG (US$123.7M), Paradigm Biocapital Advisors LP (US$123.5M), Kynam Capital Management, LP (US$118.6M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 VRDN 的基金
- Bellevue Group AG 6.73M 股 · $123.67M · Q2 2026
- Paradigm Biocapital Advisors LP 6.72M 股 · $123.52M · Q2 2026
- Kynam Capital Management, LP 6.45M 股 · $118.56M · Q2 2026
- Fairmount Funds Management LLC 5.09M 股 · $93.52M · Q2 2026
- Deep Track Capital, LP 3.59M 股 · $66.00M · Q2 2026
- Venrock Adviser, LLC 3.26M 股 · $59.85M · Q2 2026
- Avoro Capital Advisors LLC 2.50M 股 · $45.92M · Q2 2026
- Context Capital Management, LLC 40.75M 股 · $43.82M · Q2 2026
- BAKER BROS. ADVISORS LP 2.38M 股 · $43.78M · Q2 2026
- Caligan Partners LP 2.19M 股 · $40.30M · Q2 2026
- Novo Holdings A/S 2.13M 股 · $39.22M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.79M 股 · $32.93M · Q2 2026
更多关于 Davern Capital Partners, LP
常见问题
How long has Davern Capital Partners, LP held VRDN?
Davern Capital Partners, LP has disclosed VRDN holdings in 3 of the last 4 reported quarters, going back to Q4 2025.
What is Davern Capital Partners, LP's current position in VRDN?
As of Q3 2026, Davern Capital Partners, LP holds 560.71K shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $11.55M, representing 2.25% of its reported portfolio and ranking #16.
Has Davern Capital Partners, LP been buying or selling VRDN?
In the latest 13F filing (Q3 2026), Davern Capital Partners, LP newly opened its position in VRDN. The position peaked in Q3 2026 at 560.71K shares.
Which other funds hold VRDN?
Other major institutional holders of VRDN include Bellevue Group AG, Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.